Oncolytics Biotech Inc.

NasdaqCM:ONCY Stock Report

Market Cap: US$77.3m

Oncolytics Biotech Valuation

Is ONCY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ONCY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ONCY ($0.98) is trading below our estimate of fair value ($40.65)

Significantly Below Fair Value: ONCY is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ONCY?

Key metric: As ONCY is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ONCY. This is calculated by dividing ONCY's market cap by their current book value.
What is ONCY's PB Ratio?
PB Ratio11.7x
BookCA$9.06m
Market CapCA$107.90m

Price to Book Ratio vs Peers

How does ONCY's PB Ratio compare to its peers?

The above table shows the PB ratio for ONCY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.1x
CTOR Citius Oncology
4.1xn/aUS$70.6m
EPIX ESSA Pharma
0.6x43.8%US$76.8m
ETXP.F e-therapeutics
2.7xn/aUS$76.0m
AVTE Aerovate Therapeutics
0.9x43.9%US$76.8m
ONCY Oncolytics Biotech
11.7x37.5%US$107.9m

Price-To-Book vs Peers: ONCY is expensive based on its Price-To-Book Ratio (11.7x) compared to the peer average (2.1x).

Price to Book Ratio vs Industry

How does ONCY's PB Ratio compare vs other companies in the US Biotechs Industry?

61 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$507.04m
NKTX Nkarta
0.4x-11.5%US$176.42m
IMAB I-Mab
0.4x1.8%US$79.81m
ACET Adicet Bio
0.4x6.7%US$79.69m
ONCY 11.7xIndustry Avg. 1.8xNo. of Companies84PB01.63.24.86.48+
61 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ONCY is expensive based on its Price-To-Book Ratio (11.7x) compared to the US Biotechs industry average (1.8x).

Price to Book Ratio vs Fair Ratio

What is ONCY's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ONCY PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio11.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ONCY's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ONCY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.98
US$4.82
+392.0%
32.5%US$6.43US$2.50n/a4
Nov ’25US$1.18
US$4.98
+321.9%
32.5%US$6.64US$2.58n/a4
Oct ’25US$0.86
US$4.98
+478.3%
32.5%US$6.64US$2.58n/a4
Sep ’25US$0.96
US$4.84
+404.9%
35.9%US$6.58US$2.19n/a4
Aug ’25US$1.03
US$4.84
+370.1%
35.9%US$6.58US$2.19n/a4
Jul ’25US$1.00
US$4.84
+386.5%
35.9%US$6.58US$2.19n/a4
Jun ’25US$1.07
US$4.85
+352.9%
35.9%US$6.58US$2.19n/a4
May ’25US$1.12
US$4.89
+336.5%
35.9%US$6.64US$2.21n/a4
Apr ’25US$1.06
US$5.80
+447.6%
16.8%US$6.67US$4.45n/a3
Mar ’25US$1.12
US$5.67
+406.5%
16.8%US$6.52US$4.35n/a3
Feb ’25US$1.18
US$5.67
+380.8%
16.8%US$6.52US$4.35n/a3
Jan ’25US$1.35
US$5.67
+320.2%
16.8%US$6.52US$4.35n/a3
Dec ’24US$1.42
US$5.67
+299.5%
16.8%US$6.52US$4.35n/a3
Nov ’24US$1.62
US$5.82
+259.1%
16.8%US$6.68US$4.46US$1.183
Oct ’24US$2.18
US$5.82
+166.9%
16.8%US$6.68US$4.46US$0.863
Sep ’24US$2.38
US$5.82
+144.5%
16.8%US$6.68US$4.46US$0.963
Aug ’24US$2.37
US$5.92
+149.9%
16.8%US$6.81US$4.54US$1.033
Jul ’24US$2.60
US$5.75
+121.3%
16.8%US$6.61US$4.41US$1.003
Jun ’24US$1.66
US$5.75
+246.6%
16.8%US$6.61US$4.41US$1.073
May ’24US$1.59
US$5.75
+261.8%
16.8%US$6.61US$4.41US$1.123
Apr ’24US$1.20
US$5.75
+379.4%
16.8%US$6.61US$4.41US$1.063
Mar ’24US$1.53
US$5.74
+275.5%
17.2%US$6.74US$4.75US$1.122
Feb ’24US$1.85
US$5.74
+210.5%
17.2%US$6.74US$4.75US$1.182
Jan ’24US$1.63
US$5.74
+252.5%
17.2%US$6.74US$4.75US$1.352
Dec ’23US$2.12
US$5.74
+171.0%
17.2%US$6.74US$4.75US$1.422
Nov ’23US$1.30
US$5.74
+341.9%
17.2%US$6.74US$4.75US$1.622

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.86

7D

-5.2%

1Y

8.0%

Teva Pharmaceutical Industries

US$19.3b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$17.08

7D

2.0%

1Y

80.5%

Collegium Pharmaceutical

US$967.5m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.41

7D

0.5%

1Y

17.1%